Document Detail

Carfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment.
MedLine Citation:
PMID:  23538263     Owner:  NLM     Status:  In-Data-Review    
Although the incidence of multiple myeloma (MM) is increasing, the median overall survival and the number of agents in the pipeline for treating MM also are increasing. Response rates higher than 80% are not uncommon in the frontline setting when the novel agents thalidomide, lenalidomide, and bortezomib are used in combination. Response rates and survival also have improved in disease that has relapsed after treatment with conventional therapies. The focus of research has now shifted to improving survival and disease response in patients refractory to current treatment paradigms. New agents are targeting new pathways, as well as existing mechanisms known to be effective, but with different safety profiles. Carfilzomib is a potent, selective, irreversible inhibitor of the ubiquitin-proteasome pathway. The drug is a next-generation proteasome inhibitor found to be safe and effective for patients with relapsed and refractory MM, where treatment options are limited. As with any newly approved agent, one should recognize that drugs within the same class will be administered differently and often cause dissimilar treatment-related toxicities. Oncology nurses are crucial to the successful administration of chemotherapeutic agents such as carfilzomib, and an understanding of management techniques is paramount to quality patient care.
Elizabeth Bilotti
Related Documents :
11720823 - Combination chemotherapy of the taxanes and antimetabolites: its use and limitations.
8383403 - The onset of alcuronium and tubocurarine: alone and in combination.
24079623 - Management of undifferentiated embryonal sarcoma of the liver in children: a case serie...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical journal of oncology nursing     Volume:  17     ISSN:  1538-067X     ISO Abbreviation:  Clin J Oncol Nurs     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-03-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9705336     Medline TA:  Clin J Oncol Nurs     Country:  United States    
Other Details:
Languages:  eng     Pagination:  E35-44     Citation Subset:  N    
John Theurer Cancer Center, Hackensack University Medical Center in New Jersey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Chemobrain in underserved african american breast cancer survivors.
Next Document:  Chronic morphine exposure and its abstinence alters dendritic spine morphology and upregulates Shank...